Our data indicates that CDH11 is an important factor in malignant progression and is a promising therapeutic target in poor prognosis breast cancers and other CDH11 expressing malignancies such as glioblastoma, and perhaps androgen-independent prostate cancer. This evidence concerns the gene CDH11 and breast cancer.